# Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)

> **NCT05827523** · PHASE3 · RECRUITING · sponsor: **National Cancer Center, Korea** · enrollment: 520 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05827523
- **Lead sponsor:** National Cancer Center, Korea
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-31
- **Primary completion:** 2027-12-31
- **Final completion:** 2030-12-31
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2026-02-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05827523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05827523, "Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05827523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*